Century Therapeutics - IPSC Income before deduction of interest, taxes and amortization

Graphic logo of Century Therapeutics, Inc. (IPSC)

Quarterly EBITDA volume demonstrates the financial dynamics of Century Therapeutics (IPSC), where the 0.00 indicator determines the metric's magnitude. Exclusive patents on iPSC cells and stringent FDA oversight create significant barriers for competitors. The technological complexity of oncology biomanufacturing limits the entry of new players. Meanwhile, a neutral geopolitical status in the US and Germany ensures the seamless execution of global clinical trials.

IPSC Century Therapeutics, Inc. Operating profit EBITDA (11/23/2025 - 11/11/2026)

Summary analytical data breakdowns for Century Therapeutics, Inc. (IPSC)

- market value and analyst target forecast:
Market Price Century Tx|IPSC - Consensus Target
- issuer market value details:
Market Value Century Therapeutics|IPSC - Enterprise Value
- book capitalization information:
Accounting Value per Share Century Therapeutics|IPSC - Book Capitalization|Market-to-Book Ratio centurytx.com|IPSC - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Century Therapeutics|IPSC - Long-Term Debt to Equity|Short-Term Debt to Equity Century Tx|IPSC - Company Total Debt|Debt to Net Assets Ratio Century Therapeutics|IPSC - Company Long-Term Debts|Short-Term Indebtedness Century Therapeutics|Immediate Liquidity centurytx.com
- earnings and multiples data:
IPSC - Company Net Income|Net Profit Forecast Century Therapeutics|IPSC - P/E Multiple|Projected Price to Earnings Ratio Century Tx|IPSC - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Century Therapeutics|IPSC - Operating profit before deduction of amortization|Earnings per share for the last four quarters Century Therapeutics|IPSC - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months centurytx.com|IPSC - Earnings growth in current year|Expected net earnings per share growth next year Century Therapeutics
Fundamental company valuation:Century Therapeutics
Manufactured products of Century Tx

For Century Therapeutics (IPSC), whose cell therapy development model is sensitive to biological supply chain disruptions and patent risks, this indicator serves as a measure of operational viability. By analyzing actual operating profit, an investor sees a cash flow stripped of inflationary noise and one-time write-offs, where the stability of the curve confirms the business's resilience to external geopolitical shocks.

Who Century Therapeutics competes with

Legend Biotech Corp. (LEGN) - Profit before interest, taxes and amortization|SANA: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization AUTL (autolus.com)|ALLO: Operating profit EBITDA|Operating profit before deduction of amortization Selecta Biosciences|CLLS (Cellectis SA) - Operating profit EBITDA|Profit before interest, taxes and amortization Caribou Biosciences, Inc CRBU|Profit before payment of interest, taxes and amortization Instil Bio, Inc. (TIL)|Profit before payment of interest, taxes and amortization GNTA (genenta.com)|Profit before payment of interest, taxes and amortization Jasper Therapeutics, Inc. JSPR|Senti Bio - Profit before payment of interest, taxes and amortization|ADAP: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization CERO (CERo Therapeutics)|TCRT: Operating profit EBITDA|Operating profit before depreciation charges Achilles Therapeutics plc ACHL|CRGX (CARGO Therapeutics, Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization Poseida Therapeutics Inc PSTX|Profit before payment of interest, taxes and amortization 2seventy Bio (TSVT)|Gracell - Operating profit before amortization